The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for 30-Day Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

Patients who undergo autologous stem cell transplant (ASCT) for hematologic malignancies frequently have multiple comorbidities. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI), a transplant-specific modification of the Charlson Comorbidity Index, can predict risk of readm...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaglowski, Samantha M., Ruppert, Amy S., Hofmeister, Craig C., Elder, Patrick, Blum, William, Klisovic, Rebecca, Vasu, Sumithira, Penza, Sam, Efebera, Yvonne A, Benson, Don M., Devine, Steven M., Andritsos, Leslie A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192086/
https://www.ncbi.nlm.nih.gov/pubmed/25068419
http://dx.doi.org/10.1038/bmt.2014.155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192086/
https://www.ncbi.nlm.nih.gov/pubmed/25068419
http://dx.doi.org/10.1038/bmt.2014.155

Ejemplares similares